rais po ahead pivot
key inflect point pfe orphan drug strategi
current fring player orphan drug sub-categori
three upcom catalyst vyndaqel launch cardiomyopathi kol physician
feedback bullish immedi convers exist us patient long-term
orphan drug launch analysi suggest profil expand market support possibl
upsid above-consensu forecast dmd gene therapi upsid
option data vs current zero contribut data posit
plan go directli similar timelin lead competitor rivipansel
sickl cell collect three could drive valuat upsid possibl
re-rat valid orphan pipelin rais po higher
estim doubl digit ep growth pipelin option
bullish peak revenu potenti vyndaqel ttr-cardiomyopathi rare
heart diseas affect patient develop market forecast
peak like mani nascent orphan drug categori diagnosi treatment rate ttr-
cm wild type low encourag kol physician largest amyloidosi
center plan immedi convert current treat patient vyndaqel
limit risk disappoint earli launch valu proposit vyndaqel safe easi
dose reduc risk all-caus mortal base case forecast dx/tx rate
current given avail non-invas sensit diagnost launch
analog analysi support dx/tx rate translat dcf upsid
dmd nt option valid gene therapi strategi
pfe gene therapi dmd top-line data read
insuffici data make call ahead data encourag safeti lack
clinic hold subject gotten intermedi dose similar gene construct
clinic valid gene therapi srpt demonstr
srpt-like efficaci younger pt studi may also valid broader patient
benchmark less establish success would put
estimate data compar could add risk-adj npv w/
upsid valid gene therapi collabor wilson hem
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
dx/tx diagnos treat
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
view compani current valuat
undemand rel compani forward
ep growth face modest near-
term patent cliff encourag recent
event strengthen market leadership
key innov space offer attract
view sustain dividend
on-going strateg review consum busi
state intent engag post us tax
reform outcom could enhanc sharehold
vyndaqel larg market pauciti option eas use
ttr-cm awar gain traction cardiologist
posit domin stabil market view threat limit
gene therapi paradigm shift potenti
limit disclosur similar sarepta
sarepta data set high bar fast-follow
fda requir may help catch
market opportun favor
rivipansel intrigu earli data upsid limit
sickl cell patient limit treatment option
rivipansel data suggest benefit pain time discharg
phase rivipansel studi upsiz spa place
competit heat rivi could find nich
commerci outlook mini blockbust seem like
along report ad bofaml top us idea
vyndaqel larg market pauciti option
eas use
believ strong data posit pfe vyndaqel tafamidi approv juli
fda action date first fda approv treatment amyloid transthyretin
cardiomyopathi ttr-cm rare diseas result destabil ttr protein
deposit heart esc meet present data
studi show vyndaqel reduc all-caus mortal rate hospit
bloomberg consensu forecast sale versu
forecast believ main investor controversi around vyndaqel relat market
size launch uptak peak revenu potenti given diseas current
low diagnosi treatment rate preval mainli wild type
caution investor expect slow launch compani build diseas awar
base two recent check kol key opinion leader amyloid space
believ vyndaqel garner immedi use us patient alreadi manag
larg amyloidosi treatment center medium longer term believ
market pharmacotherapi significantli expand given vyndaqel mortal
benefit safeti profil eas use pill straightforward diagnosi
ttr-cm awar gain traction cardiologist
accord kol specialist enorm surg interest
attr-act data esc european societi cardiolog mushroom
patient common wild-typ diseas present larg amyloidosi
center screen tool improv kol describ non-invas diagnost techniqu
nuclear bone scintigraphi use nuclear medicin tracer local
amyloid deposit sensit earli detector ttr amyloid
particularli younger patient howev accord broader awar
diseas cardiolog commun still remain low given lack approv
treatment option ahead vyndaqel launch initi sept diseas
awar televis ad campaign known suspect detect aim
educ physician regard clue exhibit diagnos ttr-cm post-
approv hope acceler awar leverag eliqui cardiolog sale
forc promot market lead anticoagul
exhibit pfizer suspect detect diseas awar campaign diagnosi clue
analyz top orphan drug launch occur
screen base follow criteria orphan drug launch market
diagnosis/treat rate low use approach exclud cystic fibrosi
cf launch sinc cf well character market high pharmacotherapi
treatment rate aim find diseas categori manufactur
task find patient werent current treatment system focu
drug benefit label expans thu drug like alexion soliri
focus pace uptak lead paroxysm nocturn hemoglobinuria pnh
indic gener character two group orphan drug launch
genet diseas includ fabri mp mucopolysaccharidosi disord
came market earli year
market current median penetr diagnosi treatment rate
similar ttr-cm key factor genet disord find
patient diseas part depend physician abil
properli identifi patient gener view diseas pre-exist high
treatment rate newborn screen poor comp vyndaqel includ
pku phenylketonuria pomp mp view fabri form
mp better comp within categori ttr-cm
orphan diseas multi-factori diagnosi includ diseas
cataplexi associ narcolepsi pnh ipf idiopath pulmonari fibrosi
condit diagnos base combin medic histori patient
symptom varieti medic test may includ physic exam
diagnosi patient group similar multi-factori diagnosi
wild type ttr-cm
within comp estim penetr rate rang xyrem solari
year current/peak level penetr rate variabl may
reflect fact condit challeng other identifi
patient note analys highli sensit preval rate variou
epidemiolog studi comp ultra-orphan diseas epi may
chart estimate penetr genet disord orphan drug launch
chart estimate penetr orphan launch multi-factori diagnosi
note global develop market ipf year larg limit esbriet avail eu esbriet
ofev launch us end year
tabl summari comp orphan drug current estim penetr rate
pnh ahu
symptom physic test
symptom varieti molecular test
symptom varieti lab/imag test
posit domin stabil market view
threat limit
feb eido ticker initi studi attribute-cm ttr
stabil mechan vyndaqel believ gener top-line
result part studi use primari endpoint look
function statu walk test part look mortal endpoint
expect yield top-line data initi attribute-cm prior
vyndaqel approv abl avoid run head-to-head vyndaqel
believ key controversi around program abil differenti vs
vyndaqel strong data trial risk attribute-cm de facto head-to-head
studi sinc concomit use approv therapi allow first
treatment
like need strong mortal data compet vs vyndaqel
posit highli select potent stabil ttr
mimic rescu mutat howev unclear whether drug
potent stabil ttr rel vyndaqel ultim lead better clinic
outcom one main argument highli potent ttr stabil may
effect fact pfe vyndaqel fail demonstr dose-respons
attr-act studi howev kol physician point attr-act power
show dose-respons lack dose-respons may function drug
absorpt altern explan studi subject damag heart
unlik respond potent stabil therapi pertain eidx
attribute-cm studi kol believ meaning improv
better cross-trial comparison walk endpoint could garner nich use
among specialist although gener feedback major practic
cardiologist would skeptic use pure basi walk test data
assum approv part
abl quickli recruit pt ex-u
expect attribute-cm studi like consist intern
trial site vyndaqel us market august estim irb
institut review board protocol pivot trial would like get final
shortli vyndaqel us launch vyndaqel commerci avail
us make challeng physician ask patient go onto placebo even
howev kol physician believ abl quickli enrol
patient ex-u cite pfe rapid recruit patient countri
germani franc itali use non-invas imag diagnos patient
lower barrier studi enrol vs biopsi use attr-act lag start
silenc program reduc competit studi subject
mortal endpt challeng view major hurdl
physician kol view two risk attribute-cm base attr-act high
proport studi subject aliv assum trial
repres ttr-cm popul demonstr mortal improv
versu vyndaqel may challeng abil placebo-arm patient get
vyndaqel post-random view biggest trial risk
alter natur histori comparison group thu run risk under-
power studi downplay vyndaqel treatment risk note subject
attr-act studi didnt show separ mortal curv month
howev kol physician believ argument tenuou base belief
patient aliv month patient baselin class ii
subject sub-group vyndaqel expect provid immedi benefit
forecast vyndaqel global sale peak base global
diagnosis/treat rate blue sky scenario believ orphan drug comp
nascent drug market support potenti doubl diagnosis/treat rate
translat increment total peak sale
investor kol argu therapeut benefit vyndaqel rel
orphan drug comp group note vyndaqel extrem safe much easier
use comp deliv physician administ iv infus
uncertainti mainli around market size
strength preval data true population-bas surveil
studi conduct compani estim base extrapol
autopsi biopsi imag data variou small studi pfe preval
estim us global base heart failur
preserv eject fraction amyloid deposit
arriv us address market factor comorbid age similar
exercis done ex-u estim although note data less robust
model forecast base pfe preval estim
market segment attr-act vyndaqel effect patient
nyha class i-ii class subject saw higher rate hospit
vyndaqel treat patient studi subject placebo group
kol physician believ fda includ class patient vyndaqel label
given unmet need vyndaqel safeti profil wherea kol
skeptic and/or plan use drug sub-group patient
anecdot one kol larg amyloidosi center note half
ttr wild type patient class candid vyndaqel
remaind popul get drug commerci avail
note kol larg amyloidosi center select bia see sicker pt
class ii patient make major patient class and/or
commerci adopt major issu view
pfe abil expand diagnosi rate current
estim patient base compani estim includ report
patient receiv diflunis nsaid treat ttr-cm note diflunis off-
patent gener nsaid view risk therapeut substitut
post vyndaqel approv drug carri class label box warn
cardiovascular risk gate factor chronic use patient heart diseas
analyz relev orphan drug launch determin quickli
avail new treatment market effort biopharma compani
translat market penetr vyndaqel assum diagnosi
treatment rate year launch conserv estim vs comp
rang given lack population-bas surveil preval data
price major rare/orphan diseas drug meaning mortal
and/or morbid benefit rang net dont know
price vyndaqel model annual us price net
complianc adjust assumpt price access broader
market per kol pfe open-label extens studi use patient
treat attr-act studi inclus criteria loos defin
believ data open-label extens safeti studi may help physician get
comfort use vyndaqel broadli younger healthi
patient oppos attr-act inclus criteria requir subject
histori heart failur least one prior hospit clinic evid
chart bofaml estim vyndaqel launch vs comp penetr rate
pfe gene therapi program dmd duchen muscular
dystrophi potenti becom focal pipelin asset upcom data mid-
posit given size market opportun data posit
indic plan move directli singl pivot studi commercial-
stage product given report clinic data current assign
zero valu although view pend top-line import de-risk
event base exist data competitor gene therapi program
believ dose critic determin efficaci dmd present know
dose subject studi protocol allow treatment three potenti dose
level pfe mid-dos level similar sarepta gene therapi show
favor activ human studi info product profil
model sever possibl scenario assum posit translat
risk-adjust npv po
bamboo deal invest heavili manufactur
pfe gene therapi recombin capsid carri human mini-dystrophin
treat dmd acquir program deal
valuat includ up-front mileston payment gene therapi
manufactur uniqu rel biopharmaceut product build
manufactur capac suppli larg end-market trivial accord
fda want pivot test conduct commercial-stag materi
approv line fda request nvs/avexi sma program spinal muscular
atrophi reflect agenc view gene therapi asset gener accord
bamboo acquisit includ manufactur facil north carolina
fulli oper make clinic scale batch subsequ invest
hundr million get facil commerci scale manufactur capabl
may impact time-to-market assumpt competitor program
current non-commerci grade product plan pivot
commercial-stag
believ manufactur invest allow go directli
commercial-stag
gene therapi paradigm shift potenti
dmd caus genet mutat dystrophin gene lead significantli
lower level function dystrophin protein maintain integr strength
muscl initi onset symptom typic occur patient around year old
major becom wheelchair bound age die earli due
heart respiratori complic current therapi provid limit benefit
either address small subset patient popul unverifi clinic benefit
exondi target patient symptom delay diseas progress emflaza
goal dmd gene therapi address root caus dmd improv patient
abil express dystrophin research studi potenti gene
therapi treatment dmd sinc discoveri dystrophin gene one
challeng full-length size dystrophin gene exceed
packag capac accept gene therapi deliveri vector aav
research discov approach deliv truncat version dystrophin
call mini- micro-dystrophin could use function surrog
limit disclosur similar sarepta
gene therapi experiment techniqu deliv therapeut gene treat
prevent diseas driven genet defect case dmd gene therapi
treatment must deliv system affect entir bodi order reach
bodi muscl impact diseas dmd believ three key
determin impact optim dose-level safeti efficaci
implic deliveri vector gene promot transgen differ
attribut ultim impact clinic outcom remain specul
highlight similar differ rel competitor program
vector use vector vector
tabl use vector notabl differ
vector fact slightli higher percentag patient pre-exist
antibodi vs could minor
disadvantag type gene therapi vector could affect safeti
deliveri system high dose report seriou advers event
patient led temporari clinic hold underli caus unclear
view neg read-through note studi
subject clinic hold addit nv gene therapi sma also use
system deliveri high dose report concern
promot play essenti role regul express therapeut gene
three dmd gene therapi approach use differ promot although
muscle-specif activ muscl tissu tissue-specif promot
show improv durabl mitig unwant side effect
transgen therapeut gene deliv patient express mini-
micro-dystrophin treat dmd although accumul preclin studi
improv understand dystrophin essenti build block need
optim clinic benefit remain inconclus three approach differ
transgen view pfe construct similar design
transgen may also impact patent protect given three
gene therapi program still rel earli develop believ
unclear attribut impact efficaci
potenti studi dose payload similar sarepta
kol physician spoke view gene therapi payload critic variabl
efficaci program gene therapi program develop taken
slightli differ approach dose evalu singl dose wherea
investig multipl dose level lowest dose cohort
vg/kg show low level micro-dystrophin express
compani explor higher dose closer studi vg/kg
pfe test two dose vg/kg vg/kg respect
identifi activ dose preclin rat studi event dose-limit
toxic high-dos vg/kg cohort compani could initi mid-dos
cohort vg/kg howev accord
patient treat mid-dos date compani still
anticip provid updat
sarepta data set high bar fast-follow
srpt develop collabor nationwid children hospit
treat ambulatori patient year old harbor dystrophin mutat exon
report advanc encourag data among three
compani develop dmd gene therapi view data import
benchmark pfe studi treat subject achiev
encourag micro-dystrophin express mean compar normal control healthi
subject assess immunohistochemistri stain fiber
micro-dystrophin posit mean intens normal western blot
normal also show posit trend addit biomark reduct
creatin kinas muscl function improv nsaa north ambulatori
assess month treatment recent announc preliminari
result low-dos cohort show sub-therapeut micro-dystrophin
express compani evalu mid-dos cohort plan provid
updat later year
pfe trial evalu safeti toler singl intraven
infus ambulatori dmd patient year old multi-cent open-
label non-random studi interim analysi expect look
express mini-dystrophin treat patient pfe protocol differ
sarepta includ broader patient popul term age
includ patient irrespect mutat statu aforement
allow assess efficaci difficult treat popul
sarepta like inform studi design pfe upcom dmd updat
may also includ motor function data assess nsaa similar note
clinic benefit nsaa need explain context patient age base
natur histori dmd nsaa score typic increas younger patient
year age begin declin result older patient treat pfe studi may
see less increas nsaa compar data patient age
tabl comparison dmd gene therapi
mutat exon
ambulatori non-
studi target broader patient popul
sarepta solid studi could includ non-
ambulatori patient may riski early-stag
studi patient like difficult treat
higher percentag patient pre-exist antibodi
compar vs
could disadvantag
three muscle-specif promot
transgen similar sarepta
contain central hing nno bind
domain howev clinic impact differ
need clarifi
pfizer evalu low-dos vg/kg high-
dose vg/kg potenti mid-dos vg/kg
high-dos cohort show toxic sarepta mid-dos
cohort solid use vg/kg
sarepta preliminari data patient set current
bar success
patient low level
 undetect
patient muscl
fiber patient
low level
reduct ck
month
normal month
fiber intens
normal month
fda requir may help catch
although advanc dmd gene therapi program among three
compani think could potenti catch upcom data posit
base srpt interact fda compani convey fda
requir pivot studi conduct commercial-stag materi clinic
benefit muscl function approv srpt exondi receiv acceler
approv base surrog endpoint increas dystrophin express
fda may adopt stringent view gene therapi note
could potenti initi pivot commercial-grad late highlight
timelin three program tabl
tabl upcom event dmd gene therapi studi
potenti initi commercial-stag
potenti initi commercial-stag
market opportun favor
earli stage construct basic revenu model base two
gener scenario program equival sarepta thu market evenli split
competit market and/or drawback dataset result
captur one-third market assum use new
incid patient preval ambulatori patient preval popul
base current data potenti adopt non-ambulatori patient
preval popul repres signific upsid potenti demonstr
meaning benefit cardiac and/or pulmonari function late-stag patient
incorpor gener assumpt regard profit ascertain
upside/downsid valuat assum data suffici ascrib
probability-to-market assumpt similar odd success assign
bofaml biotech analyst tazeen ahmad assumpt includ cog
year two gene therapi manufactur scale net margin gene
therapi translat risk adjust npv
tabl assumpt dmd market model
rivipansel intrigu earli data
upsid limit
partner ticker rivipansel treatment
sickl cell diseas scd hold exclus licens rivipansel success
commerci would pay tier royalti rang low double-digit mid-
teen percentag net sale data singl pivot studi expect
see rivipansel potenti blockbust revenu opportun
hospital-bas drug could use treat annual scd us
novarti crizanlizumab pre-registr file expect
global blood voxelotor develop prevent scd crise rivipansel
clinic risk data small studi statist signific
quadrupl studi size go given variabl patient respons
sickl cell patient limit treatment option
sickl cell diseas group rare genet disord affect hemoglobin hb
protein molecul within red blood cell deliv oxygen scd patient develop
atyp form hemoglobin hb caus red blood cell sickl shape
caus blockag lead sever episod acut pain call vaso-
occlus crisi voc patient scd develop chronic damag tissu organ
time sever individu requir multipl annual hospit due
extrem pain pfizer rivipansel novel therapi develop acut
manag sickl cell pain crise
standard care scd patient sub-optimal
current cur treatment scd bone marrow transplant requir
match donor caus sever side effect includ graft-vs-host diseas
infect death mortal rate treatment includ blood
transfus help pain time lead develop iron
overload alloantibodi two fda-approv treatment scd
hydroxyurea gener oral drug reduc frequenc voc
patient hydroxyurea work abil increas fetal hemoglobin hbf
type hemoglobin found unborn children newborn infant
although hbf natur goe away around six month age patient
hydroxyurea abl develop hbf allow function oxygen
transport primari drawback hydroxyurea includ poor complianc estimate
risk seriou infect bleed use prophylact henc
abl acceler resolut voc episod literatur indic poor
complianc may due variou factor includ socioeconom statu
patient black box warn myelosuppress malign monitor
endari l-glutamin oral powder drug approv treat acut
complic henc far limit real-world experi endari
compar placebo clinic trial patient stabil hydroxyurea
compar placebo patient treat endari fewer hospit visit
pain treat narcot ketorolac median vs hospit visit sickl
cell pain median vs day hospit median vs occurr
patient experienc acut pain crise prophylact treatment often
requir hospit multipl day week order receiv iv pain medic
fluid hospit patient may also receiv support treatment
supplement oxygen medicin treat infect
rational rivipansel treat scd
voc pain crise scd patient mediat inflammatori compon
wherebi blood cell adher endothelium cell line insid blood vessel
caus blood cell activ express integrin form aggreg
aggreg catch rigid sickl blood cell thu lead reduc blood
flow selectin thought key part initi process given act
adhes molecul inflam endothelium carbohydr
surfac blood cell rivipansel hypothes amelior cycl act
pan-selectin antagonist bind three member selectin e- p- l- henc
reduc durat intens pain crise
rivipansel data suggest benefit pain time
preliminari proof-of-concept demonstr trial scd patient
age hospit voc random receiv standard care
plu iv administr rivipansel placebo patient assign rivipansel receiv
either low dose load dose follow everi hour high
dose load dose follow everi hour studi show
clinic meaning statist signific differ rivipansel
placebo primari endpoint time resolut voc endpoint
composit defin follow occur sustain
decreas va pain score baselin transit oral analgesia
document patient physician agre patient readi hospit
discharg written order discharg data studi includ key
secondari endpoint depict exhibit
exhibit efficaci data rivipansel scd
time-bas outcom measur hour
time resolut voc
time sustain decreas va
time transit oral analgesia
time sustain decreas va transit oral analgesia
time agreement readi discharg
time discharg
hospit length stay
accord publish manuscript trial power detect efficaci
signal effect size estim plan phase studi author note
achiev statist signific could hinder patient variabl
may accentu due adapt studi design one physician spoke
note rivipansel data pretti strike reduct clinic
meaning even werent statist signific physician thought trend
regard opioid use encourag ultim see less import
safeti profil encourag readmiss rate rais question
safeti gener balanc arm exhibit although rivipansel
higher incid rash vs patient discontinu rate higher
placebo arm biggest reason discontinu treatment group
one notabl find readmiss rate day day didnt appear
improv rivipansel treatment although readmiss rate whole trial
arm lower prior studi would suggest day day
rivipansel design acut therapi failur differenti
readmiss rate on-going trial may bolster case prophylact
treatment lieu on-demand treatment like rivipansel
exhibit frequenc scd-relat event teae
readmiss voc
readmiss voc
total reason
phase rivipansel studi upsiz spa place
follow encourag data announc reach
special protocol agreement spa fda clinic trial rivipansel
spa import indic fda board chosen design
endpoint statist analysi trial particular spa show agreement
approv endpoint time readiness-for-discharg key secondari endpoint
time discharg cumul iv opioid use discontinu iv opioid use
program reset initi june target enrol
patient top-line data expect enrol delay readout
reset summer estim studi subject enrol
expect complet accrual patient
similar trial reset evalu rivipansel acut set
patient hospit vaso-occlus crisi voc particip must
receiv iv opioid voc abl receiv first dose rivipansel
placebo within hour start iv opioid differ vs
primari endpoint chang composit voc measur time readiness-
for-discharg latter defin differ readiness-for-
discharg date/tim start date/tim first infus studi drug
modifi dosag subject year old weight receiv
rivipansel follow dose everi subject age subject
weigh receiv weight base dose maximum
follow maximum everi
spoke expert physician lead scd center note reduc
hospit stay hour would impress hour would overli
compel design felt hour improv time-to-discharg
would meaning payer patient ascrib less valu soft
secondari endpoint look opioid usag view trial design doesnt
red flag could derail program note patient requir
get iv arm one opioid anoth rivi/pbo ideal
competit heat rivi could find nich
current rivipansel posit acut therapi hospit patient
henc view biggest competit threat prophylact drug novarti
global blood would reduc obviat need
rivipansel cur approach bluebird lentiglobin gene therapi shown
promis small number patient like repres long-term competit
nv crizanlizumab formerli human anti-p-selectin
monoclon antibodi develop prevent vaso-occlus crise
scd patient rivipansel differ target l-
selectin demonstr efficaci studi sustain iv-
administ high dose per month reduc median annual rate
scd-relat pain crise vs placebo vs
without hydroxyurea low-dos show posit trend pain
crise vs compani complet addit studi
adult patient receiv open-label treatment
exploratori subset measur safeti pk/pd pharmacokinet
pharmacodynam data expect nv expect file
approv potenti launch potenti drawback
includ requir monthli iv administr efficaci didnt
translat significantli improv complianc didnt appear
signific posit impact marker hemolysi red blood cell destruct
call question whether long-term benefit prevent organ
gbt voxelotor formerli oral once-daili candid
treatment scd drug receiv fda breakthrough design thought
work increas hb affin oxygen reduc polymer
sickl red blood cell announc posit top-line result part
program june primari endpoint increas
hb week met patient
patient vs placebo patient per improv
anemia hemolysi similar patient background hydroxyurea
studi popul hydroxyurea numer fewer
voc episod activ arm vs placebo reach statist
signific result patient report outcom tool valid
prove difficult interpret henc compani plan
util key secondari endpoint per activ drug gener safe
well toler evid tissu hypoxia compani complet pre-
nda meet convey fda agre propos acceler
approv pathway voxelotor base improv hb likelihood
clinic benefit guid potenti commerci launch post-approv
confirmatori studi initi later demonstr stroke risk reduct
exhibit data scd sustain trial
week treatment period age baselin scd pain crise ltm
time first
time second
annual rate
annual rate
patient
deem unrel studi drug
exhibit preliminari data voxelotor scd part
lower
lower
result difficult interpret
increas
hemoglobin
rate voc
commerci outlook mini blockbust seem like
balanc enthusiasm remain rel temper rivipansel given prior
data evolv competit landscap believ drug carv
nich acut commun set show meaning effect voc
challeng observ scd treatment howev see number outstand
orphan drug price might stretch rivipansel reduc time
discharg littl two day henc hospit cost save like repres
upper price limit hospit charg full day push upward current
treatment option arent orphan price level hydroxyurea gener endari
list price base weight per pfe guidanc
rivipansel could reach blockbust estimate peak sale would impli price per
treatment cours rang
prophi use could obviat acut therapi theori sickest scd patient
prefer prophylact treatment rather wait acut pain episod
monthli iv administr isnt ideal proven reduc
voc episod given work similar mechan rivipansel
prophi patient breakthrough pain crise like wouldnt receiv rivipansel one
doctor spoke even hypothes novarti could give away free drug
hospit get patient start mainten therapi initi
subcutan trial statu and/or path forward potenti at-
home use unclear us voxelotor repres anoth prophi option
conveni oral per doc check make patient feel substanti better
howev doctor like skeptic see benefit voc long-term
safeti data given risk hypoxia especi concurr hydroxyrea
cur therapi repres disrupt threat scd monogenet
disord henc one initi target emerg gene-alt
therapi widespread adopt like far away approach pose
threat cure scd would negat need rivipansel
stage develop ascrib valu rivipansel neglig consensu
sale respect potenti opportun best proxi like exist voc
hospit data per cdc around hospit due voc
episod us averag hospit charg episod rang
assum voc hospit rate stay like
unrealist given prophylact treatment use high end price justifi
larg effect size still fall short blockbust market penetr
believ rivipansel potenti peak sale drug
multipl peak revenu add po
exhibit hypothet us market opportun acut scd treatment
high end hospit charg voc episod
penetr
bofaml global research compani data cdc us agenc healthcar research qualiti
note claim number conting payment
includ royalti addit develop mileston
regulatori mileston commerci mileston
price object po base blend averag dcf forward price-to-earnings po
impli stock could trade ep current multipl
consensu ep multipl base regress
analysi histor us major pharma forward month price-to-earnings multipl year
forward compound-annual-growth-rate ep believ dcf analysi base reason assumpt
includ sale compound-annual-growth-rate driven key growth brand
xeljanz ibranc xtandi post-lyrica loe flat sale growth follow
downward rebas us sale pipelin overal
sale forecast out-year sale dcf assum wacc
tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
